By Small Pharma Analyst:Vertex (VRTX) is a 25-year old biopharma company that has had more than its share of ups and downs over the years - and yet another company-defining event is just around the corner.
Robert Weinstein submits:
The Way means inducing the people to have the same aim as the leadership, so that they will share death and share life, without fear of danger. -- Sun Tsu, The Art of War.
Vertex Pharmaceuticals Incorporated (VRTX) of Cambridge, MA was up strongly today to close at $49.95 a share.
Vertex Pharmaceuticals Incorporated (VRTX) stock rose about 3.5% during yesterday's trading session, and is up another 1.29% in after-hours, on news that a US Food and Drug Administration's (FDA) advisory panel voted 13-2 in favor of expanding the company’s cystic fibrosis drug Kalydeco label to include a wider range of patients affected by the rare lung disease.
Vertex Pharmaceuticals Incorporated (VRTX) is scheduled to announce earnings for the second quarter of its 2014 fiscal year (2QFY14) on July 29, after the market closes. Analysts expect a 14.7% year-over-year decrease in earnings. The revenue for the quarter is expected to decrease 58.3% year-over-year to $131.9 million.
Bert Wilkison submits:On 04/07/11, Vertex Pharmaceuticals (VRTX) made headlines when it announced that one of its long time collaborators, Cystic Fibrosis Foundation Therapeutics, agreed to provide up to $75M over the next five years to support research and development for some of Vertex's early stag
By Brian L. Wilson:Anyone who was watching Vertex Pharmaceuticals (VRTX) yesterday (October 11th, 2012) probably noticed the huge ~5% drop that was followed with an immediate reversal and subsequent decline. Vertex is normally a very calm and slow-moving stock, so any VRTX investors caught off guard may have added to the volatility with reactionary decisions.